Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma.

Brain tumor pathology - 1 Oct 2021

Kim Seong-Ik, Lee Kwanghoon, Bae Jeongmo, Lee Sungyoung, Yun Hongseok, Park Chul-Kee, Choi Seung Hong, Maquiling Christopher Alec, Park Sung-Hye, Won Jae-Kyung

Abstract excerpt

Vimentin is a marker of epithelial-mesenchymal transformation and indicates poor prognosis in various cancers, but its role in diffuse gliomas remains unknown. We investigated the vimentin expression of diffuse gliomas according to the upcoming 2021 WHO classification, its variations due to mutational status, and its prognostic effects. We analyzed vimentin immunohistochemistry in 315 gliomas: a test set...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Oligodendroglioma

Share to Vimentin

Source

Identifiers

PMID: 34338912
DOI: 10.1007/s10014-021-00411-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Revisiting vimentin: a negative surrogate marker of molecularly defined oligodendroglioma in adult type diffuse glioma.PMID 34338912Read ↗

Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Semantic proximity Read ↗

Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.Semantic proximity Read ↗

Adult type diffuse gliomas in the new 2021 WHO Classification.Semantic proximity Read ↗

Expression Profiling of IDH, p53, ATRX, and KI-67 Immunostains as Potential Grid for Molecular Subtyping of Adult Diffuse Gliomas from PakistanSemantic proximity Read ↗

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.Semantic proximity Read ↗

Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification.Semantic proximity Read ↗

Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.Semantic proximity Read ↗

The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas.Semantic proximity Read ↗

Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.Semantic proximity Read ↗

A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.Semantic proximity Read ↗

Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.Semantic proximity Read ↗

GFAP Alternative Splicing and the Relevance for Disease – A Focus on Diffuse GliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.